Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent
暂无分享,去创建一个
P. Fenaux | M. Pla | J. Poupon | C. Chomienne | F. Guidez | B. Cassinat | F. Zassadowski | R. Padua | M. Chopin | O. Chourbagi | K. Pokorná | N. Ferré | L. Llopis
[1] Stephen L. Abrams,et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2013, Leukemia.
[2] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[3] C. Chomienne,et al. Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. , 2012, Cellular signalling.
[4] P. S. Klein,et al. Maintenance of Hematopoietic Stem Cells through Regulation of Wnt and mTOR Pathways , 2012, Nature Medicine.
[5] Barry P. Young,et al. The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division , 2012, Cell cycle.
[6] Gabriela Alexe,et al. The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. , 2012, The Journal of clinical investigation.
[7] L. Sun,et al. GSK3 is a regulator of RAR-mediated differentiation , 2012, Leukemia.
[8] H. de Thé,et al. Curing APL through PML/RARA degradation by As2O3. , 2012, Trends in molecular medicine.
[9] S. Collins,et al. GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells , 2011, Leukemia.
[10] P. Fenaux,et al. New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation , 2011, Molecular and Cellular Biology.
[11] Robert Lindeman,et al. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth. , 2010, Experimental hematology.
[12] F. Fornai,et al. Intracellular pathways underlying the effects of lithium , 2010, Behavioural pharmacology.
[13] Kevin S. Smith,et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.
[14] H. Stunnenberg,et al. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. , 2010, Cancer cell.
[15] H. Dombret,et al. PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL , 2010, Leukemia.
[16] H. Dombret,et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.
[17] S. Lalevée,et al. Phosphorylation control of nuclear receptors. , 2010, Methods in molecular biology.
[18] W. Tong,et al. Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.
[19] H. Dombret,et al. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). , 2009, Leukemia research.
[20] I. Weissman,et al. Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation , 2009, Proceedings of the National Academy of Sciences.
[21] Jia Luo,et al. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.
[22] Carlos A. Garcia,et al. Toll-Like Receptor-Mediated Production of IL-1Ra Is Negatively Regulated by GSK3 via the MAPK ERK1/21 , 2009, The Journal of Immunology.
[23] Cécile Rochette-Egly,et al. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs) , 2009, Nuclear receptor signaling.
[24] Mark J. Murphy,et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.
[25] L. Robb,et al. Cytokine receptors and hematopoietic differentiation , 2007, Oncogene.
[26] Jiang-Ning Zhou,et al. Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia , 2007, Neuropharmacology.
[27] Daniel G. Tenen,et al. Transcription factors in myeloid development: balancing differentiation with transformation , 2007, Nature Reviews Immunology.
[28] R. Moon,et al. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation , 2006, Nature Medicine.
[29] A. Sartorelli,et al. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia. , 2004, Leukemia research.
[30] H. Son,et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo , 2004, Journal of neurochemistry.
[31] M. Robin,et al. PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia , 2003, Nature Medicine.
[32] B. Doble,et al. GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.
[33] D. Chuang,et al. Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities , 2003, Neuroscience.
[34] A. Zeiher,et al. Glycogen Synthase Kinase-3 Couples AKT-dependent Signaling to the Regulation of p21Cip1 Degradation* , 2002, The Journal of Biological Chemistry.
[35] S. Chevret,et al. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. , 2001, Blood.
[36] M. Koken,et al. Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .
[37] S. Kogan,et al. Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia , 1999, The Journal of experimental medicine.
[38] M. Koken,et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Sugawara,et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. , 1998, Blood.
[40] I. Weissman,et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .
[41] I. Weissman,et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[42] P. Cohen,et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.
[43] P. Fenaux,et al. In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. , 1995, Leukemia.
[44] P. Pandolfi,et al. Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.
[45] P. Chambon,et al. Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[46] S. Collins,et al. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha) , 1990, Molecular and cellular biology.